Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin versus N-acetylcysteine as adjuncts to standard Helicobacter pylori eradication therapy
IRCT20231017059756N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Helicobacter pylori infection comparing Control: standard triple therapy + placebo, Rosuvastatin + standard triple therapy and N-acetylcysteine + standard triple therapy (3 arms). Primary endpoint: Effectiveness of drugs in the treatment of Helicobacter pylori infection. Started Oct 2023; status: completed.
02
Drugs
rosuvastatinacetylcysteine
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20231017059756N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231017059756N1.